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Abstract
Background: The hereditary spastic paraplegias (HSPs) are rare neurodegenerative gait disorders which are
genetically highly heterogeneous. For each single form, eventual consideration of therapeutic strategies requires an
understanding of the mechanism by which mutations confer pathogenicity. SPG8 is a dominantly inherited HSP,
and associated with rather early onset and rapid progression. A total of nine mutations in KIAA0196, which encodes
the WASH regulatory complex (SHRC) member strumpellin, have been reported in SPG8 patients so far. Based on
biochemical and cell biological approaches, they have been suggested to act via loss of function-mediated
haploinsufficiency.
Methods: We generated a deletion-based knockout allele for E430025E21Rik, i.e. the murine homologue of
KIAA0196. The consequences on mRNA and protein levels were analyzed by qPCR and Western-blotting,
respectively. Motor performance was evaluated by the foot-base angle paradigm. Axon outgrowth and relevant
organelle compartments were investigated in primary neuron cultures and primary fibroblast cultures, respectively.
A homemade multiplex ligation-dependent probe amplification assay enabling identification of large inactivating
KIAA0196 deletion alleles was applied to DNA from 240 HSP index patients.
Results: Homozygous but not heterozygous mice showed early embryonic lethality. No transcripts from the
knockout allele were detected, and the previously suggested compensation by the wild-type allele upon
heterozygosity was disproven. mRNA expression of genes encoding other SHRC members was unaltered, while
there was evidence for reduced SHRC abundance at protein level. We did, however, neither observe HSP-related in
vivo and ex vivo phenotypes, nor alterations affecting endosomal, lysosomal, or autophagic compartments. KIAA0196
copy number screening excluded large inactivating deletion mutations in HSP patients. The consequences of
monoallelic KIAA0196/E430025E21Rik activation thus differ from those observed for dominant HSP genes for which a
loss-of-function mechanism is well established.
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Conclusions: Our data do not support the current view that heterozygous loss of strumpellin/SHRC function leads
to haploinsufficiency and, in turn, to HSP. The lethality of homozygous knockout mice, i.e. the effect of complete
loss of function, also argues against a dominant negative effect of mutant on wild-type strumpellin in patients.
Toxic gain-of-function represents a potential alternative explanation. Confirmation of this therapeutically relevant
hypothesis in vivo, however, will require availability of appropriate knockin models.
Keywords: Hereditary spastic paraplegia, KIAA0196, Mouse model, Knockout, SPG8, Strumpellin
Background
Hereditary spastic paraplegia (HSP) refers to a group of
rare disorders in which progressively spastic gait is the
major and often primary symptom. The pathological cor-
relate of this phenotype is a distal-to-proximal degener-
ation of upper motoneuron axons in the corticospinal tract
[1]. While HSPs have long been categorized according to
age at onset, mode of inheritance, and presence/absence of
additional symptoms, a genetic classification scheme is cur-
rently taking over. To date, more than 70 spastic paraplegia
gene loci (SPGs) have been reported [2, 3].
HSP type SPG8 is an autosomal dominant form which
is associated with a comparatively young age at onset
and a pure, but rather severe phenotype [4, 5]. In 2007,
KIAA0196 mutations were identified in six SPG8 pedi-
grees [5], but only six more families have been published
since [6–10]. KIAA0196 codes for strumpellin, a 1159-
residue protein which contains a short central spectrin
repeat but otherwise seems to lack recognizable hom-
ology domains [5]. Strumpellin is a member of the mul-
tiprotein WASH regulatory complex (SHRC) [11, 12].
This complex associates with retromer, another multi-
protein complex, and regulates the tubular extension of
early endosomes [11, 13–16]. It may thereby facilitate
cargo sorting for endosome-to-Golgi retrieval, for mem-
brane receptor recycling and/or for targeting to the lyso-
somal degradative pathway [11, 17, 18]. Distinct
additional roles in autophagy have been proposed more
recently [19–21].
Eight unique KIAA0196 missense mutations have been
associated with HSP so far [5–10]. By affecting residues
226, 471, 583, 591, 619, 620, 626, and 696, they seem to
cluster in the protein’s central part. Interestingly, an
overlapping central region is also affected by a genomic
deletion of exons 11–15 (encoding residues 470–672)
[8]. Functional assays have been performed for some of
the missense variants, but did not reveal any alterations
regarding subcellular localization, interaction potential,
SHRC assembly, retromer binding, and endosomal
tubulation [12, 22, 23]. In contrast, RNAi-mediated
knockdown of strumpellin was found to have strong
effects in cell lines [11, 14, 22, 23] and in zebrafish
embryos including abnormal development of spinal
cord motoneurons [5, 22]. Collectively, these findings
have been interpreted in light of the mutational
mechanism relevant for SPG8: they were suggested to
argue against a dominant negative effect of mutant
strumpellin alleles on the wild-type allele, but to, instead,
indicate loss-of-function-mediated haploinsufficiency [8,
22, 23]. Against this background, the apparent absence of
classical loss-of-function mutations (i.e. non-sense, frame-
shift, splice-site, whole gene deletions) in SPG8 patients
was attributed to a lack of appropriate tools (e.g. for de-
tecting deleted alleles) and/or compensation by the non-
inactivated allele [23].
In the present study we used genetic and in vivo ap-
proaches to further elucidate the potential mechanisms
by which mutations in KIAA0196 cause HSP. Our find-
ings strongly question the current haploinsufficiency hy-
pothesis. As they also provide additional evidence
against relevance of a dominant negative effect of mu-
tant on wild-type strumpellin, we discuss alternatives
and provide a conceptual basis for experimental testing.
Methods
Generation of mouse lines
By screening of a 129/SvJ mouse genomic λ library
(Stratagene) with a probe derived from intron 14 of
E430025E21Rik, i.e. the murine homologue of
KIAA0196, we obtained a 7.6 kb SpeI fragment which
spans introns 9 to 15. This fragment was cloned into the
pKO-V901 plasmid (Lexicon Pharmaceuticals, The
Woodlands, TX) which contains a phosphoglycerate kin-
ase (pgk) promoter-driven diphtheria toxin A cassette as
a negative selection marker. Applying several sub-
cloning steps, a single loxP site was inserted into an
NspI site 216 bp downstream of exon 12, while an AscI
site was placed 265 bp upstream of exon 12 and used for
inserting a pgk promoter-driven neomycin resistance
cassette flanked by frt-sites and preceded by another
loxP site (Fig. 1a). Following electroporation of this tar-
geting construct into embryonic stem (ES) cells accord-
ing to standard procedures, Neomycin-resistant clones
were analyzed by Southern Blotting of XbaI-digested ES
cell DNA. One of the positive clones was injected into
C57BL6 blastocysts. The resulting chimeras were
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subsequently backcrossed with C57BL6 to obtain hetero-
zygously targeted mice. Mating with lines that express
either cre- or flp-recombinase resulted in the heterozy-
gous constitutive and conditional exon 12 deletion lines,
respectively (Fig. 1a). Studies were performed with litter-
mates of the F3 generation. Genotypes were determined
by PCR on DNA isolated from tail biopsies (primer se-
quences available upon request). All animal experiments
were approved by the responsible local authorities (TLV,
internal reference “SPG8 Mäuse”).
Quantitative PCR and western blotting
Mice were anesthetized and perfused with 25 ml PBS.
Brains were removed and snap-frozen in liquid nitrogen.
For quantitative PCR (qPCR), 30 mg of cerebral cortex
were homogenized in a glass-glass potter and total RNA
isolated with the RNeasy kit (Qiagen, Hilden, Germany)
following the manufacturer’s instructions. qPCR was
performed in a 20 μl amplification mixture consisting of
Brilliant® II SYBR Green QPCR Master Mix (Stratagene,
La Jolla, CA), cDNA (equivalent to 25 ng reverse-
transcribed RNA) and primers (250 nM final concentra-
tion each; sequences available upon request). Transcripts
were amplified with Rotor Gene 6000 (Corbett Life Sci-
ence, now Qiagen). Expression levels were calculated
using the Pfaffl equation [24], normalized against Tubb3,
and geometrical means from three animals expressed as
fractions of wild-type values. For Western blotting, brain
hemispheres were homogenized in RIPA lysis buffer
containing protease inhibitor cocktail cOmplete (Roche
Diagnostics, Rotkreuz, Switzerland), and centrifuged at
13.200 rcf for 3 min. 10 μl of supernatant were loaded
on 10 % polyacrylamide gels and transferred onto PRO-
TRAN nitrocellulose membranes (Whatman GmbH,
Dassel, Germany). Blots were probed with antibodies
against strumpellin (C-14, Santa Cruz Biotechnology,
Dallas, TX), FAM21 [25] (antiserum kindly provided by
Matthew N. Seaman), and α-tubulin (T9026, Sigma-
Aldrich, St. Louis, MO), and signals obtained by apply-
ing appropriate horseradisch peroxidase-conjugated
Fig. 1 Targeted deletion of E430025E21Rik exon 12, and determination of consequences at mRNA and protein levels. a Wild-type (“wt”) and targeted
allele (“tg”), and recombinase-mediated generation of the conditional (“flp”) and the constitutive (“cre”) deletion. ex, exon; NEO, neomycin resistance
cassette; triangles, loxP sites; half-circles, frt sites. b RT-PCR on brain-derived cDNA with forward and reverse primers in exon 11 and exon
13, respectively. Note the smaller extra product (arrow) which is specific to cre-derived template. c Sequence analysis of product marked
in (B). d qPCRs on brain-derived cDNA. For E430025E21Rik, the exons targeted in three distinct assays are indicated. Diagrams depict normalized
geometrical means (n = 3); error bars represent SEM. e Western blot-based quantification of strumpellin and Fam21 in brain lysates after normalization
to α-tubulin. Diagram depicts normalized means (n = 3), error bars represent SEM
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secondary antibodies. Quantification of signal intensity
was done by standard densitometry of scanned Western
blot images.
Phenotyping
Two independent cohorts of animals (aged 28–52 weeks
and 59 to 76 weeks, respectively) were investigated every
four to five weeks. The foot-base angle, previously
shown to be highly sensitive in detecting HSP-related
gait abnormalities in mice [26, 27], was applied as de-
scribed [28]. Briefly, the angle which hind-paw and sur-
face enclose at toe-off positions was quantified using
single video frames from recordings of beam walking
mice (Fig. 2a). 12 randomly chosen steps from two to
three consecutive runs were considered. Prior to starting
monthly phenotyping, animals were weighted. The sig-
nificance of differences between genotype-specific values
was analyzed timepoint-wise by the 2-sided Student’s T-
test after Bonferroni correction.
Primary cell cultures
Cortical neurons were prepared from P0 or P1 animals,
and cultured as described [29]. Cells were fixed after
96 h and immunostained for the pan-axonal neurofila-
ment marker SMI312. Images of neurons with SMI312
positive neurites (i.e. axons) were acquired at 40x magni-
fication. Axonal branches were counted, and axon length
was measured in ImageJ; means for genotypes were
compared by the two-sided Student’s T-test.
Mouse adult fibroblasts (MAFs) were prepared from
2-months-old mice following a standard protocoll [30].
Cells were grown for 10 days, seeded into 8-well cham-
ber slides (Lab-Tek™; ThermoFisher Scientific, Waltham,
MA), and grown for another 2 days. For transfection of
an LC3-RFP construct (kindly provided by C. Kaether)
lipofectamine (Invitrogen, now Life Technologies,
Carlsbad, CA) was used. Cells were fixed in 4 % para-
formaldehyde, permeabilized in 0.1 % Triton X-100/
PBS for 15 min, and incubated in blocking buffer
containing goat serum for 30 min. Endosomes and ly-
sosomes were visualized by immunfluorescence
against EEA1 (Ab2900; Abcam, Cambridge, UK) and
LAMP-1 (553792; BD Pharmigen, CA, USA), respect-
ively. Anti Snx1 (sc-10609; Santa Cruz Biotechnology,
Dallas, TX) was used to specifically visualize endo-
somes with protruding tubulations. Images were ob-
tained by confocal laser scanning microscopy
(LSM710 Meta; Zeiss, Oberkochen, Germany).
Patients and controls
Two independent cohorts of HSP index patients were
analyzed. The first one consisted of 148 patients of mainly
French origin. Pure and complex HSP had been diagnosed
in 74 cases each. Family history was consistent with
dominant inheritance in 138, while 10 cases were sporadic.
All patients were negative for mutations in SPAST (SPG4),
while mutations in ATL1 (SPG3A) had only been excluded
when age at onset was <20 years. The second cohort con-
sisted of 92 patients (42 and 50 with pure and complex
HSP, respectively) from central European countries. In 83
cases there was evidence for dominant inheritance (two
successive generations affected), while the remaining cases
were compatible with both dominant and recessive inherit-
ance. Informed consent had been obtained prior to genetic
analysis from all patients. Anonymized DNA samples from
unrelated projects were used as controls.
Fig. 2 Comparative phenotyping of wild-type vs. heterozygous
E430025E21Rik animals in two independent cohorts. a Determination
of the foot-base angle (FBA) by videotaping the beam-traversing
animal from behind. b FBA over time. Brackets denote cohort
identity (n = 3-13 for younger cohort; n = 9 for older cohort);
error bars represent SD. c Body weight for males and females.
Animal identity, brackets and error bars as in (b)
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KIAA0196-specific multiplex ligation-dependent probe
amplification assay
Genomic sequence of the human KIAA0196 gene was
downloaded from the USCS genome browser (www.ge-
nome.ucsc.edu), and all 29 exons of the major isoform
(NM_014846) marked. A total of six exonic MLPA
probes were placed along the gene such as to achieve
roughly equal spacing (Fig. 4a). Probe design was done
according to criteria provided by MRC-Holland (The
Netherlands) at www.mlpa.com (see Additional file 1:
Figure S1 for sequences of the corresponding MLPA
probe oligonucleotides). Six reference probes targeting
physically distinct genomic regions were derived from
previously established probesets ([31, 32], unpublished).
Oligonucleotides for MLPA probes were from MWG
Eurofins (Ebersberg, Germany). MLPA reactions utilised
reagents from MRC-Holland, and products were
visualised on a LICOR4200 (LICOR Biosciences, Lin-
coln, NE). Relative MLPA signals were calculated as
described previously [33].
Results
Genomic deletion of KIAA0196 exon 12 creates a
homozygously lethal knockout allele which reduces SHRC
abundance in heterozygosity
In order to model loss of strumpellin function in mice,
we decided for a classical cre/loxP strategy which targets
exon 12 of the murine KIAA0196 homologue
E430025E21Rik (Fig. 1a). F1 animals carrying one exon
12-deleted allele were viable and fertile, and gave hetero-
zygous offspring in the expected 50 % ratio when
crossed back with C57BL/6 wild-type animals. Matings
in which both parents were heterozygous (henceforth re-
ferred to as E430025E21Rikwt/ko animals) failed to result
in homozygous offspring. As this suggested prenatal le-
thality, we analyzed embryonic stages E19.5, E16.5, and
E13.5. While E430025E21Rikwt/wt and E430025E21Rikwt/
ko were generally found in a ~1:2 ratio, not a single
E430025E21Rikko/ko was detected amongst 63 embryos
(Table 1), and no signs of terminated embryonic
development were observed in dissected uteri. This sug-
gests that strumpellin is necessary for survival of very
early embryonic stages and/or for attachment of blasto-
cyts to the epithelial lining of the maternal uterus.
In brain-derived cDNA of heterozygous animals, RT-
PCR with primers in exon 11 and exon 13 resulted in
two bands: one band of normal size and one additional
smaller one (Fig. 1b). The latter contributed less than
0.1 % of total product, was absent in wild-type samples,
and represented an mRNA species in which exon 13 dir-
ectly follows exon 11 as confirmed by sequence analysis
(Fig. 1c). The weakness of this RT-PCR signal is likely
explained by non-sense mediated decay due to presence
of a pre-terminal stop codon in the altered exon 13
reading frame. The exon 12 deletion thus created a true
knockout allele.
Heterozygous inactivation of a gene may result in up-
regulation of expression from the wild-type allele. We
therefore designed a set of E430025E21Rik-specific
qPCR primers, and analyzed brain-derived cDNA. Our
finding of a ~50 % reduction in the total amount of
E430025E21Rik transcript (Fig. 1d) in heterozygous ani-
mals indicates that there is no compensation by the
wild-type allele at mRNA level. With enhanced protein
stability representing another potential compensatory
mechanism we also analyzed brain lysates by Western
blotting, and found that the reduction in E430025E21Rik
mRNA abundance directly translates into reduced abun-
dance of strumpellin protein (Fig. 1e). A similar degree
of reduction was observed for the SHRC core protein
Fam21 (Fig. 1e), while mRNA expression of several
genes encoding SHRC members was unaltered (Fig. 1d).
Heterozygous presence of an E430025E21Rik knockout
allele thus results in less strumpellin protein and a cor-
respondingly reduced abundance of the multi-protein
SHRC complex.
A reduction in strumpellin/SHRC levels does not entail
HSP-related phenotypes
In order to determine whether the observed reduction in
the amount of strumpellin/SHRC results in a movement
phenotype we performed foot-base angle measurements
(Fig. 2a), i.e. a paradigm which has proven very sensitive
in revealing early onset, progressive gait impairment in
murine models for other forms of HSP (e.g. [26, 27]).
The foot-base angles in heterozygous animals did not
differ from those of wild-type siblings (Fig. 2b). Also in
contrast to what is observed in many other HSP models
(e.g. [27, 34]), body weight for both sexes was normal at
all ages (Fig. 2c). Collectively, these data suggested that
the reduced amount of strumpellin/SHRC is sufficient
for maintaining a normal overall phenotype, particularly
normal motor performance.
Table 1 Distribution of genotypes obtained from
E430025E21Rikwt/ko x E430025E21Rikwt/ko matings
Genotype
Age wt/wt wt/ko ko/ko p-value
P1 12 25 0 2.4 x 10−5
E19.5 2 3 0 0.23
E16.5 3 8 0 0.042
E13.5 4 6 0 0.056
Total 21 42 0 1.3 x 10−8
Ratio 1 2 0
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Ex vivo axon outgrowth as well as endosomal tubulation
and the integrity of organelle compartments are
unaltered upon heterozygous presence of an
E430025E21Rik knockout allele
Although HSP is considered a degenerative rather than a
developmental disease [1], ex vivo axon outgrowth assays
have revealed aberrations for numerous clinically valid
mouse models [27, 35, 36]. We therefore cultured cor-
tical neurons from P1 animals and stained them for an
axon marker. After four days, i.e. when significant alter-
ations are already obvious in neurons from other models
(e.g. [27]), we did not detect any abnormalities including
for critical parameters such as total axon length and
number of axonal branches (Fig. 3a). Heterozygosity for
an E430025E21Rik knockout allele does therefore not
negatively impact on axon outgrowth.
Our protein level observations argued for a reduced
amount of total SHRC in heterozygotes in vivo (see
Fig. 1e). Completely ablating SHRC has been shown to
result in increased endosomal tubulation [11, 23], in the
collapsing of the endosolysosomal network [17], and in a
strong de-regulation of autophagy [19–21]. We therefore
cultured mouse adult fibroblasts (MAFs) from wild-type
and from heterozygous strumpellin knockout mice, and
investigated the corresponding organelle compartments.
Immunfluorescence against Snx1 revealed similar frac-
tions of cells containing tubulated endosomes (Fig. 3b).
Based on the general endosomal and lysosomal markers
EEA1 and LAMP1, respectively, these compartments ap-
peared completely normal as regards organelle size,
number, and cellular distribution (Additional file 2: Fig-
ure S2). Similarly, transfection of a fluorescently tagged
fusion protein of the autophagosome/autolysosome
marker LC3 failed to reveal any autophagy-related ab-
normalities (Additional file 2: Figure S2). Our moderate
reduction of strumpellin/SHRC levels, thus, does not
trigger the drastic morphological abnormalities observed
upon complete ablation.
Genetics further questions the strumpellin/SHRC
haploinsufficiency hypothesis for HSP
In parallel to generating a murine E430025E21Rik
knockout allele, we aimed at screening HSP patients for
bona fide knockout mutations. We reasoned that dele-
tions encompassing the whole gene or at least its 5′ part
would represent such definite loss-of-function alleles. As
these genomic rearrangements are not detectable by
standard sequencing-based approaches, we developed a
KIAA0196-specific MLPA kit (Fig. 4a). We first validated
it on a set of control DNAs and on a sample carrying a
rare SNP at one of the MLPA probes’ ligation site
(Fig. 4b). The application to 240 samples from HSP
index patients, however, did not identify any KIAA0196
copy number aberration (Fig. 4c).
Considering that neither small truncating mutations
nor large inactivating deletions are apparently present in
HSP patients we aimed at a comparison with other dom-
inant HSP genes that are associated with clinically pure
HSP. For SPAST (SPG4) and REEP1 (SPG31), i.e. two
frequently involved genes [37, 38], haploinsufficiency is
well-supported [26, 39]. In contrast to KIAA0196, stop
Fig. 3 Investigation of potential consequences of heterozygous
E430025E21Rik knockout ex vivo. a Quantification of axon length and
axonal branching in primary cortical neurons which were stained for
the axon marker SMI312 96 h after plating. Scale bars: 20 μm; error
bars represent SD. b Visualization of endosomal tubules (arrows) in
primary mouse adult fibroblasts by immunofluorescence against the
retromer subunit Snx1. The fraction of cells with at least one tubule
was determined in 30–40 cells in three independent experiments.
Scale bars: 10 μm; error bars represent SD
Jahic et al. Orphanet Journal of Rare Diseases  (2015) 10:147 Page 6 of 10
mutations, small indels, and large inactivating deletions
of either SPAST or REEP1 are frequently found in HSP
patients (Table 2). Also of note is the absence of small
SPAST and REEP1 truncating variants in a large cohort
of individuals presumably not suffering from HSP, com-
pared to the presence of three such KIAA0196 variants
(Table 2). These differences regarding the spectrum of
mutations and variants further argue for a difference re-
garding the mutational mechanism.
Discussion
Our study aimed at testing the current haploinsuffi-
ciency hypothesis for the autosomal dominant HSP type
SPG8. As a first pertinent approach, we generated a
murine E430025E21Rik allele that lacks an out-of-frame
exon. As we found virtually no corresponding mRNA in
vivo, probably because of nonsense-mediated decay [40],
this alteration effectively generated a knockout allele.
Contrary to what has been suggested [23], the
heterozygous presence of such an inactivating mutation
neither resulted in compensatory up-regulation of
mRNA expression from the wild-type allele nor in sub-
stantially enhanced stability of the strumpellin protein.
Heterozygous presence of a knockout allele therefore en-
tails a reduction of the amount of strumpellin.
Near complete reduction of strumpellin levels by
RNAi-mediated knockdown has been shown to severely
destabilize other SHRC subunits [11, 12]. We show that
the ~35 % reduction in strumpellin levels observed upon
heterozygous knockout results in a similar degree of re-
duction for Fam21 levels. This is consistent with the
proposed general dependence of SHRC subunit stability
on proper assembly of the complex [11–13, 17].
Reduced abundance of SHRC in heterozygous strum-
pellin knockout cells likely results in correspondingly re-
duced overall SHRC activity. The physiological role of
SHRC is not yet completely understood, but recent stud-
ies suggested an involvement in maintaining the
Fig. 4 KIAA0196 copy number screening by multiplex ligation-dependent probe amplification (MLPA). a To scale scheme of KIAA0196 gene with exons
represented by vertical bars. Arrows indicate targets of MLPA probes. ex, exon. b validation of MLPA probe mix on 12 control DNAs (summarized as
box plots) and on a sample known to carry a rare SNP at the ligation site for the exon 29-specific probe (circles). The 0.7 to 1.3 signal range indicative
of normal copy number is marked in grey. co, control MLPA probes targeting independent chromosomal arms as indicated. c Exemplary
results for ten HSP index patients
Table 2 Mutation and variation spectra for selected dominant HSP genes
Gene (HSP sybtype) SPAST (SPG4) REEP1 (SPG31) KIAA0196 (SPG8)
Relevant pathomechanism Haploinsufficiency Haploinsufficiency (controversial)
Large inactivating deletion mutations in HSP patients yes [33] yes [44] no [present study]
Fraction of small stop/indel mutations in HSP patients ~45 % [45] ~60 % [44, 46] 0 % [10, and references therein]
Small stop/indel variants listed in exome variant server 0 0 3
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structure/complexity of the endo- and lysosomal com-
partments [17], in inhibiting autophagy [19], but also in
promoting autophagy [20, 21]. The effects of blocking
SHRC function in these studies were rather severe and
included collapsing of organelle compartments and ag-
gregate formation. We did, however, not observe any
evidence for abnormal endosomes, lysosomes, or autop-
hagosomes/autolysosomes in heterozygous strumpellin
knockout MAFs. We also found no increase in endoso-
mal tubulation, i.e. a major consequence of (near)
complete reduction of the major SHRC subunit Wash1
[11, 23]. This suggests that, in contrast to complete
SHRC inactivation, moderately reduced SHRC abun-
dance/activity is enough to maintain grossly normal
function of the corresponding organelle systems.
There were also no phenotypic consequences associ-
ated with a reduction of murine strumpellin/SHRC in
vivo. One may argue that axon length and maximum age
would render mice unsuited models for HSPs in the first
place. Numerous recent studies, however, have shown
impressive and clearly disease-relevant phenotypes in
murine models for progressive axonopathies. These in-
clude knockouts of two genes that have been shown to
cause pure dominant HSP by haploinsufficiency: for
both SPAST (spastin protein, SPG4) and REEP1 (REEP1
protein, SPG31) there is progressive gait impairment,
the severity of which negatively correlates with the
amount of wild-type protein available [26, 41, 42]. While
reducing the amounts of either spastin or REEP1 is thus
pathogenic, this does not seem to apply to strumpellin/
SHRC.
Bona fide KIAA0196 knockout mutations have thus far
not been found in human HSP patients. There are, how-
ever, only few pertinent screens reported, and tools for
detecting deleted alleles have been lacking. A second
part of our study thus addressed the potential presence
of inactivating large deletions. The application of a
homemade MLPA assay to 240 HSP index patients failed
to reveal this class of mutations. Again, the comparison
to the haploinsufficiency HSP genes SPAST and REEP1
is of interest, as both their mutation and variation spec-
tra turn out to be very different from those of KIAA0196
(Table 2). The genetic data available therefore further
indicate that strumpellin knockout alleles are well toler-
ated when present heterozygously. The generalization
of this, i.e. that heterozygous absence of any SHRC
member is tolerated, is suggested by the fact that the
DECIPHER database [http://decipher.sanger.ac.uk/] lists
several heterozygous whole gene deletions for each
SHRC member, but none of the corresponding cases
is tagged with a clinical movement phenotype. Taken
together, our in vivo and genetic data as well as currently
available database entries do not support a relevance of
haploinsufficiency for SPG8.
The major alternative to haploinsufficiency in domin-
antly inherited disease is a dominant negative effect of
mutant on wild-type protein, thereby effectively leading
to complete loss-of-function. However, the embryonic
lethality of our homozygous knockout mice, which par-
allels early embryonic death of homozygous Wash1
knockouts [17, 19], is not compatible with complete
loss-of-function in otherwise healthy HSP patients.
Against this background, we note a recent report of a re-
cessive KIAA0196 mutation affecting the very 3′ part of
the coding sequence: the mutation, which is predicted to
maintain only residual activity, does not confer an upper
motoneuron phenotype, but results in cardiac, cerebellar,
and craniofacial abnormalities [43]. These symptoms
probably correspond to what is observed upon (incom-
plete) strumpellin knockdown in zebrafish [22].
Given that neither haploinsufficiency nor a domin-
ant negative effect seem to mediate pathogenicity of
HSP-associated strumpellin alterations, what does?
We propose to consider a toxic gain-of-function effect
caused by the accumulation of misfolded protein.
Along this line, the interaction of strumpellin with
the aggregation-prone VCP protein, and its presence
in several neurodegeneration-associated intracellular
deposits is noteworthy [22]. The fact that no aggrega-
tion has been observed upon overexpression of mu-
tant strumpellin [23] may simply reflect the large
differences in the time scale (several hours in cell cul-
ture vs. early adulthood clinical consequences in pa-
tients). Fully resolving the mutational mechanism in
SPG8 will probably require appropriate knockin in
vivo models.
Conclusion
Our study does not lend support to the current haploin-
sufficiency hypothesis for SPG8, and also corroborates
non-relevance of a dominant negative effect of mutant
on wild-type strumpellin. It can thus be expected to
initiate novel experimental approaches towards under-
standing and, eventually, treating SPG8. More generally,
it emphasizes that determination of the mutational
mechanism should be regarded an indispensable step for
each genetically determined disorder.
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Additional file 1: Figure S1. KIAA0196-specific MLPA probes. Shown
are exons against which probes were designed, plus neighbouring
intronic sequence. The MLPA probe binding sequence is underlined.
White underlined space indicates the ligation site. Marked in yellow is the
stop codon in the terminal exon 29, while the nucleotide marked in red
represents SNP rs188863489 which served as a positive control. Stretches
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Additional file 2: Figure S2. Visualization of lysosomes (LAMP-1), early
endosomes (EEA1), and autophagosomes/lysosomes (LC3-RFP) by
immunofluorescence (LAMP-1, EEA1) and transfection of an
autofluorescent marker (LC3-RFP) in primary adult mouse fibroblast
cultures. Scale bars: 20 μm. (TIFF 1055 kb)
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